


**Remarks**

Applicants have amended the specification to incorporate the priority claim.

The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Thus, claims 1 and 16 are as originally presented. Claims 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 15 are currently amended. Claims 13 and 14 are cancelled. No new matter has been added by these amendments. Also, Applicants reserve the right to prosecute any cancelled subject matter in timely-filed continuation applications. Applicants further believe the application is in condition for allowance, and respectfully request the same.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100855-1P US.

Respectfully submitted,



---

Name: Heidi Berven  
Dated: June 17, 2005  
Reg. No.: 48,951  
Phone No.: 781-839-4336  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 01760